Chung et al. examine the levels of glycoprotein non-metastatic melanoma protein B (GPNMB) in the blood of patients with renal cell carcinoma who acquire resistance to immune checkpoint inhibitor therapy. Findings show that GPNMB levels are elevated and could serve as a prognosticator of and potential treatment target for treatment-resistant cancer.
- Jin-Sung Chung
- Vijay Ramani
- Kiyoshi Ariizumi
